There are a lot of assumptions in your post, Falconer. You state that there will not be any competition, but this may not be the case. We all hope that it will be, but even Anavex has something in its pipeline that may be superior to Blarcamesine. Don't be too quick to dismiss what other companies will figure out once they, too, pivot their attention toward novel approaches as we're seeing with Anavex, SAVA, and many other startups that have ditched plaque theory.
News 
Market Data 
Discover 
